PharmaCyte Biotech Inc (PMCB)

[1234jklm]

We're increasing our payments to Austrianova to 50% from10%?

Why?

PharmaCyte has agreed to share with Austrianova 50% of any financial and non-financial consideration it receives from sublicenses under the Asset Purchase Agreement, the Diabetes Licensing Agreement and the Cannabis Licensing Agreement

We already have an agreement to pay 10%. Why increase it to 50%?

For a reduction of a few progress payments?

The devil is in the details so we need to see those.

Initially it looks like we are giving away 40% of our profit just as this is looking like being very valuable.

Why?

Why change the agreement so much against us at this stage.

Under the first agreement to buy bio bluebird we owned the licensing rights to ciab

Then it was limited to just diabetes cabbinoids and cancer. So we lost stem cells which is the most valuable.

Now it looks like our share of profits is being reduced again.

Read carefully about the stem cells included in this, they are only for diabetes.

Is kw working for us or Austrianova?

I want to see the details but this doesn't sound good to me.